| |
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility. .png)
|
|
| By Kevin Dunleavy By agreeing to donate royalties on its U.S. sales of bladder cancer drug Bavencio, Pfizer has received the go-ahead to finalize its $43 billion buyout of Seagen, the company said on Tuesday. Pfizer expects to close the merger on Thursday. The company also announced a restructuring of its organization, with leadership changes. |
|
|
|
By Annalee Armstrong All of a sudden, radiopharmaceuticals are the hottest game in town—outside of antibody drug conjugates, of course. GlobalData reports that venture capital deals in the space have grown 550% to $408 million this year. |
By Angus Liu Alongside a historic approval for the first therapy utilizing the Nobel Prize-winning CRISPR/Cas9 gene-editing technology, the FDA has cleared a rival gene replacement therapy, also for sickle cell disease (SCD). |
By Nick Paul Taylor Bristol Myers Squibb has filled the antibody-drug conjugate-shaped hole in its pipeline by following the increasingly well-trodden path to China, handing SystImmune $800 million upfront for a phase 1/2 solid tumor candidate as part of a deal worth up to $8.4 billion. |
By Ben Adams Less than two years after snapping up the chief commercial role at Moderna, Arpa Garay is stepping aside amid a shake-up in the Big Biotech’s commercial unit. |
By Fraiser Kansteiner Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit, the company confirmed Friday. |
By Gabrielle Masson After receiving the FDA greenlight for its sickle cell disease (SCD) gene therapy, Vertex Pharmaceuticals is paying $100 million for rights to Editas Medicines’ Cas9 gene-editing tech, a deal that encompasses freshly approved Casgevy amid a long-running patent battle. |
By Andrea Park This week, Tandem Diabetes Care’s t:slim X2 insulin pump made headlines as the first to integrate with Dexcom’s latest G7 sensor to create an artificial pancreas system. A mere 24 hours later, they’re already having to share the spotlight. |
By Kevin Dunleavy A Sanofi manufacturing facility in France, which was temporarily closed five years ago for emitting dangerous emissions, is under fire again after a leak caused the release of the same neurotoxin, bromopropane. |
By Helen Floersh A collaboration between the Allen Institute, the Chan Zuckerberg Initiative and the University of Washington aims to build new technologies that let scientists measure changes in single cells in real time. |
Fierce podcasts Don’t miss an episode |
| Children’s Specialized Hospital, part of RWJBarnabas, is providing recreation, sports and social programs for kids with special healthcare needs. This week on "Podnosis," Anastassia Gliadkovskaya sat down with Matthew McDonald, M.D., the hospital’s president and CEO, to discuss what it takes to offer these services in-house and the future of pediatric care. |
|
|---|
|
|
|
Tuesday, December 19, 2023 | 12pm ET / 9am PT Either you want to implement a CLM, or you don’t know how to fix the processes of the one you have in place. Either is a tough place to be in. Join us in this webinar to learn from a CLM solution implementation expert in the highly regulated field of pharmaceuticals. Register now. 
|
|
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. S3 Connected Health |
Whitepaper qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
Whitepaper Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
Whitepaper If you find yourself grappling with bioanalytical challenges during the drug development process, rest assured that these obstacles can be overcome - discover more! Sponsored by: Sannova Analytical |
Whitepaper Discover how cloud-based HPC and AI can transform drug discovery and accelerate time-to-market. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper DSCSA Compliance with a Trusted Partner Sponsored by: BioCare |
Whitepaper Your guide to accessing, managing, and licensing the content that fuels AI, machine learning, and data visualization projects across the enterprise. Sponsored by: CCC |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Want to know the Top 5 criteria for selecting the ‘right’ CDMO for pDNA manufacturing? Sponsored by: Syngene |
| |
|
